Zenas BioPharma, Inc.
NASDAQZenas BioPharma heads into its May 15 results with one of the most aggressive short-interest builds in recent memory — and a CEO who has been buying into the decline with his own cash. Short sellers have dramatically increased pressure over the past month. At nearly 20% of the free float, short interest has climbed 17% in a single week and more than 20% over the past month. The…
Snapshot as of 15 May 2026
Zenas BioPharma heads into its May 15 results with one of the most aggressive short-interest builds in recent memory — and a CEO who has been buying into the decline with his own cash. Short sellers have dramatically…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ZBIO — free to start on ORTEX.
Sign up for free →Open ZBIO on ORTEX